TSC22 domain family member 1Genealiases: HUCEP-2 · Ptg-2 · TGFB1I4 · TSC22
Q-omics provides the consensus-scored TSC22D1 profile across patient tissues and cancer cell-line models. TSC22D1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TSC22D1 is differentially expressed in 9, with the highest sampling consensus in BLCA. Additionally, TSC22D1 protein abundance shows 31,601 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, BLCA, and GBM as cancer lineages where TSC22D1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TSC22D1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TSC22D1 survival associations across molecular data types. TSC22D1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (8) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TSC22D1 RNA expression–survival associations across cancer types. High TSC22D1 expression shows unfavorable associations in UVM and ACC, but favorable associations in KIRC, THCA, LGG and COAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TSC22D1 RNA expression.
This table summarizes TSC22D1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 12. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TSC22D1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TSC22D1 shows lower tumor expression in BLCA, KICH, LUAD, BRCA and LUSC and higher tumor expression in THCA. The BLCA box plot shows higher TSC22D1 RNA expression in normal versus tumor tissue (log2 FC = −1.638, t-test p < 0.001).
This table shows molecular features associated with TSC22D1 in patient tissues and cancer cell lines. In patient samples, TSC22D1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TSC22D1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Leukemia.
